Novo's main Ozempic plant cited for quality lapses by FDA
Novo Nordisk's plant in Denmark is facing FDA quality issues, impacting supply of popular diabetes and obesity medications Ozempic and Wegovy.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearing
The U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
Bernie Sanders grills Ozempic maker over high prices
Novo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.
Analysts say market forces will lower cost of obesity drugs
Congressional pressure likely won't significantly affect the pricing of Novo Nordisk's drugs, Ozempic and Wegovy.
Ozempic 'very likely' to have price slashed
Ozempic is expected to be included in upcoming negotiations for price reductions under the US government's new drug pricing policies.
Forget the shot. A weight loss pill saw promising results in Phase 1 testing
Amycretin, a new pill, could offer a convenient weight loss alternative to Ozempic, showing potential for significant weight loss within three months.
Novo's main Ozempic plant cited for quality lapses by FDA
Novo Nordisk's plant in Denmark is facing FDA quality issues, impacting supply of popular diabetes and obesity medications Ozempic and Wegovy.
'Stop ripping us off': Ozempic producer CEO in hot seat in congressional hearing
The U.S. pays significantly higher prices for Ozempic and Wegovy compared to other countries, prompting scrutiny from Senate leaders.
Bernie Sanders grills Ozempic maker over high prices
Novo Nordisk CEO faced scrutiny in Congress over drug pricing and its moral implications for patients, especially in relation to high prices and access to medication.
Analysts say market forces will lower cost of obesity drugs
Congressional pressure likely won't significantly affect the pricing of Novo Nordisk's drugs, Ozempic and Wegovy.
Ozempic 'very likely' to have price slashed
Ozempic is expected to be included in upcoming negotiations for price reductions under the US government's new drug pricing policies.
Forget the shot. A weight loss pill saw promising results in Phase 1 testing
Amycretin, a new pill, could offer a convenient weight loss alternative to Ozempic, showing potential for significant weight loss within three months.
Weight-loss drug firm accused of prioritising profits after halting insulin pen production
Novo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds
Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Wegovy Approved to Cut Heart Disease and Stroke Risk
Weight loss drugs approved for heart health benefits
Semaglutide linked to cardiovascular risk reduction
Novo Nordisk's record-breaking growth highlights 'insatiable demand' for weight loss drugs
Novo Nordisk achieved a 20-year high in revenue growth rate, beating estimates for FY2023 revenue and earnings.
The growth is not demand constrained but production capacity constrained, with an insatiable demand for weight loss drugs.
Inside the Ozempic factory: How a $430 billion Danish pharma giant feeds America's appetite for weight-loss drugs
Denmark has one of the lowest obesity rates in Europe, but it has been on the rise.
Novo Nordisk, a Danish pharmaceutical company, has developed drugs that can help regulate blood sugar and aid in weight loss.
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug
Shares in Novo Nordisk down 1.1% post-publication of data analysis favoring Eli Lilly's Mounjaro for greater weight loss.
Weight-loss drug firm accused of prioritising profits after halting insulin pen production
Novo Nordisk's decision to halt production of insulin pens raises ethical concerns over prioritizing profits from weight-loss drugs over patients' health.
Doctors Concerned About Drugmakers Testing Ozempic-Style Injections on Six-Year-Olds
Novo Nordisk's study shows liraglutide can effectively reduce BMI in children aged 6-12, yet it raises concerns about long-term safety and developmental impact.
Wegovy Approved to Cut Heart Disease and Stroke Risk
Weight loss drugs approved for heart health benefits
Semaglutide linked to cardiovascular risk reduction
Novo Nordisk's record-breaking growth highlights 'insatiable demand' for weight loss drugs
Novo Nordisk achieved a 20-year high in revenue growth rate, beating estimates for FY2023 revenue and earnings.
The growth is not demand constrained but production capacity constrained, with an insatiable demand for weight loss drugs.
Inside the Ozempic factory: How a $430 billion Danish pharma giant feeds America's appetite for weight-loss drugs
Denmark has one of the lowest obesity rates in Europe, but it has been on the rise.
Novo Nordisk, a Danish pharmaceutical company, has developed drugs that can help regulate blood sugar and aid in weight loss.
Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug
Shares in Novo Nordisk down 1.1% post-publication of data analysis favoring Eli Lilly's Mounjaro for greater weight loss.
Chamber, MSF Weigh in on Senate HELP Committee Hearing with Novo Nordisk CEO
The U.S. Chamber opposes price controls, claiming they hinder innovation and access to medications amid scrutiny of rising drug prices.
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk's new weight loss drug monlunabant shows promising results but raises concerns due to increased risk of psychiatric side effects compared to placebo.
The next big market for weight-loss drugs: children
Novo Nordisk's Saxenda can significantly reduce children's BMI, showing potential for FDA approval in a market with currently no approved obesity medications for children.
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptions
Many patients are struggling to find their medications due to ongoing shortages, despite recent claims from drug manufacturers that supplies have improved.
Wegovy reduced COVID deaths in obese patients, study shows
Wegovy significantly reduced deaths and illness from COVID-19 during a large study, showcasing its benefits beyond weight loss.
Does Wegovy Work for Longterm Weight Loss? New Study Says Yes | Entrepreneur
Wegovy leads to 10% weight loss maintenance over four years for obesity patients without diabetes.
25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway
Novo Nordisk's significant increase in Wegovy users and sales shows a growing demand for weight loss drugs.
Is Wegovy Covered By Insurance? These Insurers Offer Coverage | Entrepreneur
Major health insurance companies in the U.S. are starting to cover Novo Nordisk's weight loss injection Wegovy.
The FDA approved Wegovy for heart health after a study showed it could reduce the risk of heart attack and stroke by 20%.
Wegovy is no longer just a weight-loss drug
Wegovy was approved by the FDA to reduce the risk of major cardiovascular events in obese or overweight adults with established cardiovascular disease.
Wegovy has been shown to reduce the risk of major adverse cardiac events by 20%, cardiovascular death by 15%, and death from any cause by 19%.
Wegovy reduced COVID deaths in obese patients, study shows
Wegovy significantly reduced deaths and illness from COVID-19 during a large study, showcasing its benefits beyond weight loss.
Does Wegovy Work for Longterm Weight Loss? New Study Says Yes | Entrepreneur
Wegovy leads to 10% weight loss maintenance over four years for obesity patients without diabetes.
25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway
Novo Nordisk's significant increase in Wegovy users and sales shows a growing demand for weight loss drugs.
Is Wegovy Covered By Insurance? These Insurers Offer Coverage | Entrepreneur
Major health insurance companies in the U.S. are starting to cover Novo Nordisk's weight loss injection Wegovy.
The FDA approved Wegovy for heart health after a study showed it could reduce the risk of heart attack and stroke by 20%.
Wegovy is no longer just a weight-loss drug
Wegovy was approved by the FDA to reduce the risk of major cardiovascular events in obese or overweight adults with established cardiovascular disease.
Wegovy has been shown to reduce the risk of major adverse cardiac events by 20%, cardiovascular death by 15%, and death from any cause by 19%.
Sanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Europe's most valuable company Novo Nordisk reports a slight increase in profits
Novo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
The introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Denmark gets Novo Nordisk to lower Ozempic prices
Sanders calls out Novo Nordisk for high drug prices as Denmark faces cost crisis.
Europe's most valuable company Novo Nordisk reports a slight increase in profits
Novo Nordisk posted a slight increase in net profit for the second quarter and raised its forecast for the full year due to increased demand for its diabetes and obesity treatments.
Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
The introduction of generic versions of weight-loss injectable drugs is expected to lead to increased uptake due to lower costs.
Sen. Bernie Sanders launches Senate investigation into 'high' pricing of Ozempic, Wegovy
Sen. Bernie Sanders investigating high drug prices for Ozempic and Wegovy.
Senate Committee Investigates Ozempic and Wegovy Costs
The Senate Committee is investigating Novo Nordisk's high prices for Ozempic and Wegovy medications, urging the company to consider lowering costs for better accessibility.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project
Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
Denmark's new Nvidia AI supercomputer will come online this year
Nvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.
The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.
The foundation behind Ozempic maker Novo Nordisk is funding an Nvidia-backed AI supercomputer project
Novo Nordisk is investing in an AI supercomputer through collaboration with Nvidia for drug discovery and other scientific advancements.
The Novo Nordisk Foundation's investment in the AI supercomputer is aimed at accelerating groundbreaking scientific discoveries and fostering collaboration between academia and industry.
Denmark's new Nvidia AI supercomputer will come online this year
Nvidia and Novo Nordisk are collaborating to establish an advanced AI supercomputer in Denmark named Gefion, boosting research in various fields.
The supercomputer Gefion, powered by Nvidia's GPUs, will support the Danish Center for AI Innovation and be hosted using 100% renewable energy.
Study shows no evidence of suicidal thoughts caused by Ozempic, Wegovy
A large U.S. study found no evidence of a link between Novo Nordisk's Ozempic and Wegovy and an increase in suicidal thoughts.
The study found that semaglutide, the active ingredient in Ozempic and Wegovy, actually had a lower risk of new and recurrent suicidal thoughts compared to other medications for weight loss or diabetes.
Five hundred new jobs coming in Chartres, south of Paris
Danish pharmaceutical giant Novo Nordisk is investing â¬2.1 billion in a French production site to expand the capacity and manufacturing of its anti-obesity drug.
Novo Nordisk's Semaglutide medication, originally meant for diabetes, is also effective against obesity and has massive global potential.
Goldman Sachs predicts that the global market for anti-obesity medication could reach $100 billion by 2030.
Ozempic and Wegovy could soon be challenged by China's generic competitors
Intensifying competition in Chinese market for Novo Nordisk's diabetes drug Ozempic and weight loss treatment Wegovy.